Robert Francois Hobbs, PhD

Advances in ‘first-principles’ models of radiation response allow, in principle, for accurate mechanism-aware prediction of how biological effectiveness and effective linear quadratic (LQ) parameters change across various experimental and clinical conditions....

Quantitative image-based dosimetry for radiopharmaceutical therapy (RPT) increasingly relies on large, multi-organ mechanistic models of physiologically based pharmacokinetics (PBPK). While PBPK models often fit clinical data well, the extent to which their i...

We present a small-animal SPECT-CT system based on CZT imaging spectrometers and a rapidly switchable dual-FOV apertures. The system supports both total-body imaging and focused, high-resolution imaging. These capabilities address a key need in preclinical ra...

In prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for metastatic castration-resistant prostate cancer, salivary glands often receive unintended high absorbed doses and are considered dose-limiting organs. For radiopharmaceutica...

Combining external-beam radiation therapy (EBRT) with radiopharmaceutical therapy (RPT) is gaining momentum as the two modalities complement each other from a radiation-biology perspective. EBRT delivers precise, high-dose radiation to bulky, image-defined le...

Clinical Trials Specialty Program

Personalized dosimetry in radiopharmaceutical therapy (RPT) is gaining strong interest because fixed-activity regimens often fail to capture the large variability in how patients respond to the treatment. Growing evidence shows clear dose–response relationshi...

Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Radiopharmaceuticals, Theranostics, and Nuclear Medicine

αRPT is a promising treatment modality that is largely impervious to the mechanisms of resistance associated with chemotherapy, conventional radiotherapy, targeted (pathway-inhibition) therapies, and immunotherapy. Osteosarcoma (OS), which frequently expresse...